Wide Ranks

ATAI

ATAI Life Sciences N.V.

1.73

Top Statistics
Market Cap 290 M Forward PE -2.56 Revenue Growth -54.00 %
Current Ratio 5.81 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.11 Enterprise / Revenue 653.65 Price To Sales Trailing12 Months 877.03
Profitability
Profit Margins 0.00 % Operating Margins -56505.00 %
Balance Sheet
Total Cash 85 M Total Cash Per Share 0.5350 Total Debt 23 M
Total Debt To Equity 16.27 Current Ratio 5.81 Book Value Per Share 0.9070
All Measures
Short Ratio 630.00 % Message Board Id finmb_710359021 Fax 49 89 2153 90351
Shares Short Prior Month 9 M Return On Equity -0.6277 City Berlin
Uuid 8699f3bf-7398-34d0-b0ba-129948e2583d Previous Close 1.69 First Trade Date Epoch Utc 1 B
Book Value 0.9070 Total Debt 23 M Volume 1 M
Price To Book 1.91 Fifty Two Week Low 1.02 Total Cash Per Share 0.5350
Total Revenue 331000 Shares Short Previous Month Date 1 B Target Median Price 8.00
Max Age 86400 Recommendation Mean 1.33 Sand P52 Week Change 0.3133
Operating Margins -56505.00 % Target Mean Price 8.00 Net Income To Common -128603000
Short Percent Of Float 0.0771 Implied Shares Outstanding 167 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M Average Volume10days 2 M
Total Cash 85 M Next Fiscal Year End 1 B Revenue Per Share 0.0020
Held Percent Insiders 0.0999 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.69 Target Low Price 5.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.27 Open 1.67
Dividend Yield 0.00 % Return On Assets -0.2541 Time Zone Short Name EST
Trailing Eps -0.8000 Day Low 1.67 Address1 Wallstrasse 16
Shares Outstanding 167 M Price Hint 4 Target High Price 11.00
Website https://www.atai.life 52 Week Change 0.6635 Average Volume 1 M
Forward Eps -0.6800 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 437.40 % Is_sp_500 False Regular Market Day High 1.76
Profit Margins 0.00 % Debt To Equity 16.27 Fifty Two Week High 2.85
Day High 1.76 Shares Short 9 M Regular Market Open 1.67
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 653.65
Revenue Growth -54.00 % Shares Percent Shares Out 0.0588 Currency USD
Time Zone Full Name America/New_York Market Cap 290 M Is_nasdaq_100 False
Zip 10179 Quote Type EQUITY Industry Biotechnology
Long Name Atai Life Sciences N.V. Regular Market Day Low 1.67 Held Percent Institutions 0.2677
Current Price 1.73 Enterprise To Ebitda -2.11 Financial Currency USD
Current Ratio 5.81 Gross Margins 100.00 % Industry Disp Biotechnology
Number Of Analyst Opinions 4 Country Germany Float Shares 123 M
Two Hundred Day Average 1.55 Enterprise Value 216 M Price To Sales Trailing12 Months 877.03
Forward PE -2.56 Regular Market Volume 1 M Ebitda -102440000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Atai Life Sciences N.

V.

, a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression.

The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.

In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder.

Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression.

ATAI Life Sciences N.

V.

was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.